These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 6362866

  • 1. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA.
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA.
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [Abstract] [Full Text] [Related]

  • 3. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
    Rosenberg SA, Eberlein TJ, Grimm EA, Lotze MT, Mazumder A, Rosenstein M.
    Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
    [Abstract] [Full Text] [Related]

  • 4. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 5. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L, Fefer A.
    Cancer Res; 1972 Nov 15; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract] [Full Text] [Related]

  • 6. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F.
    J Clin Invest; 1998 Jan 15; 101(2):429-41. PubMed ID: 9435316
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.
    Rosenstein M, Eberlein TJ, Rosenberg SA.
    J Immunol; 1984 Apr 15; 132(4):2117-22. PubMed ID: 6607955
    [Abstract] [Full Text] [Related]

  • 8. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results.
    Bartholeyns J, Lopez M, Andreesen R.
    Anticancer Res; 1991 Apr 15; 11(3):1201-4. PubMed ID: 1888150
    [Abstract] [Full Text] [Related]

  • 9. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
    Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA.
    J Immunol; 1984 Apr 15; 132(4):2123-8. PubMed ID: 6607956
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z, Tang C, Xu S, Zhang B, Zhang X, Moyana T, Yang J, Xiang J.
    Cell Mol Immunol; 2007 Aug 01; 4(4):277-85. PubMed ID: 17764618
    [Abstract] [Full Text] [Related]

  • 15. Cancer immunogene therapy.
    Yoshizawa H, Kagamu H, Gejyo F.
    Arch Immunol Ther Exp (Warsz); 2001 Aug 01; 49(5):337-43. PubMed ID: 11798131
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK, Palmer LD, Perry-Lalley D, Bolton ES, Alexander RB, Horan PK, Yang JC, Muirhead KA.
    Cancer Res; 1993 May 15; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K, Leggatt GR, Zhong J, Liu X, de Kluyver RL, Peters T, Fernando GJ, Liem A, Lambert PF, Frazer IH.
    J Natl Cancer Inst; 2004 Nov 03; 96(21):1611-9. PubMed ID: 15523090
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.